The NSABP B52 phase III trial randomized patients with HR+/HER2+ BC (n = 315) to receive neoadjuvant chemotherapy plus a dual HER2-targeted blockade (trastuzumab plus pertuzumab) with or without an AI (plus a luteinizing hormone-releasing hormone analog (LHRHa) if premenopausal) [95]. This evidence concerns the gene HR and breast cancer.